Plain-English translation of NCT03802773 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a stem cell transplant approach for people with blood cancers like leukemia or lymphoma. Doctors will transplant healthy blood-forming cells from donated cord blood, combined with a strong chemotherapy preparation and a medication called cyclophosphamide given after the transplant. This new combination is designed to help the transplanted cells grow successfully while reducing a common and serious complication called graft-versus-host disease.
Cord blood stem cell transplants can cure blood cancers, but they come with risks—especially graft-versus-host disease, where the new immune cells attack the patient's body. This trial is testing whether this medication strategy can improve transplant success and safety.
You likely qualify if…
You likely don't qualify if…
You will be admitted to the hospital for intensive treatment. First, you'll receive strong chemotherapy to prepare your body for the new stem cells. Then you'll receive the cord blood transplant. After the transplant, you'll take the protective medication (cyclophosphamide and others) to prevent rejection and graft-versus-host disease. You'll stay in the hospital and be closely monitored with blood tests and physical exams to track how well the new cells are growing and how your immune system is recovering.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Italy